Pheochromocytoma as a Clinical Model of Peripheral Sympathetic Overdrive: Old and New Findings.
Adrenergic receptors
Pheochromocytoma
Reflex control of the cardiovascular system
Secondary hypertension
Sympathetic activity
Journal
Current hypertension reports
ISSN: 1534-3111
Titre abrégé: Curr Hypertens Rep
Pays: United States
ID NLM: 100888982
Informations de publication
Date de publication:
10 10 2019
10 10 2019
Historique:
entrez:
11
10
2019
pubmed:
11
10
2019
medline:
30
5
2020
Statut:
epublish
Résumé
The present paper will review the results of experimental and clinical studies aimed at defining the functional behavior of the central and peripheral nervous system in adrenal pheochromocytoma. The contribution of sympathetic neural influences to the development of high blood pressure values in pheochromocytoma is complex. Studies performed in experimental animal models have shown that hypertension and the concomitant high circulating levels of catecholamines can lead to inhibition of central sympathetic neural outflow by reflex mechanisms and direct stimulation of central adrenergic receptors, respectively. However, these studies have also shown that high circulating levels of catecholamines favor a downregulation of alpha- and beta-adrenergic receptors, lessening their response to endogenous and exogenous adrenergic stimulation. The present paper reviews results of human studies performed by our group and others on the behavior of the central and peripheral nervous system in human pheochromocytoma. We discuss data collected in patients with different levels of peripheral sympathetic drive, i.e., before and after surgical removal of the adrenal pheochromocytoma. In the presence of elevated plasma catecholamine level, such as that characterizing adrenal pheochromocytoma, microneurography shows that central sympathetic neural activity is normal or even inhibited. At the peripheral vascular level, pheochromocytoma is characterized by a reduced vascular reactivity to exogenous sympathetic stimulation but a normal response by the vessels to endogenous adrenergic stimulation.
Identifiants
pubmed: 31599352
doi: 10.1007/s11906-019-0989-9
pii: 10.1007/s11906-019-0989-9
doi:
Substances chimiques
Catecholamines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
90Références
Endocrinology. 1983 Jul;113(1):354-61
pubmed: 6861707
J Hypertens. 2019 Sep;37(9):1746-1756
pubmed: 30950979
Physiol Rev. 1990 Oct;70(4):963-85
pubmed: 1977182
Circ Res. 1987 Jul;61(1):86-98
pubmed: 3038368
Circ Res. 2015 Mar 13;116(6):976-90
pubmed: 25767284
Hypertension. 1999 Sep;34(3):461-5
pubmed: 10489394
Hypertension. 2018 Aug;72(2):483-491
pubmed: 29915014
Endocr Regul. 2011 Apr;45(2):65-90
pubmed: 21615192
Hypertension. 1982 May-Jun;4(3 Pt 2):193-9
pubmed: 7040238
J Pharmacol Exp Ther. 1987 Jun;241(3):870-4
pubmed: 3598906
J Clin Endocrinol Metab. 2014 Jun;99(6):1915-42
pubmed: 24893135
Circ Res. 2014 May 23;114(11):1804-14
pubmed: 24855203
Front Physiol. 2012 Jul 24;3:284
pubmed: 22934037
Cardiol Rev. 2017 Sep/Oct;25(5):215-222
pubmed: 28786897
Hypertension. 2002 Feb;39(2 Pt 2):513-8
pubmed: 11882600
Hypertension. 1990 Feb;15(2 Suppl):I128-31
pubmed: 2298468
J Hypertens. 2014 Nov;32(11):2120-9; discussion 2129
pubmed: 25275242
J Hypertens. 1988 Jan;6(1):9-15
pubmed: 3351298